Part of NATIONAL HEALTH SERVICE
Clinical Trials
288
41 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
27
9.4%
Completed
87
30.2%
Enrolling By Invitation
3
1.0%
Not yet recruiting
11
3.8%
Recruiting
46
16.0%
Suspended
1
0.3%
Terminated
11
3.8%
Unknown
98
34.0%
Withdrawn
4
1.4%
No approval data available
- The London Cancer Hub receives approval for a £1bn expansion that will create 3,000 new jobs and add one million square feet of laboratory and research space in Sutton. - The expansion is projected to contribute £1.2bn in Gross Value Added to the UK economy while strengthening the country's position in global oncology research. - The development aligns with the UK government's Life Sciences Sector Plan and National Cancer Plan for England, aimed at maintaining competitiveness amid recent industry setbacks.
- A phase II trial of zongertinib as first-line treatment for advanced HER2-mutant lung cancer achieved a 77% overall response rate, with 8% of patients experiencing complete tumor disappearance. - The targeted therapy demonstrated disease control in 96% of patients, offering a new treatment option for the 4% of lung cancer cases driven by HER2 mutations. - Results presented at ESMO Congress represent the first study of zongertinib as initial treatment, with a phase III trial planned to compare against standard chemotherapy.
- The UK IMPORT LOW trial's 10-year follow-up confirms that partial-breast and reduced-dose radiotherapy maintain similar efficacy to whole-breast radiotherapy in low-risk early breast cancer patients. - Ipsilateral breast tumor recurrence rates remained low across all treatment groups, with 2.8% for whole-breast, 1.9% for reduced-dose, and 3.0% for partial-breast radiation at 10 years. - Adverse effects were minimal across all groups, with breast shrinkage occurring in less than 10% of patients and supporting partial-breast radiotherapy as standard of care. - The findings provide long-term evidence for de-escalated radiation approaches in carefully selected patients with low-risk early-stage breast cancer.
- Researchers developed an AI test that can predict which men with high-risk prostate cancer will benefit most from abiraterone treatment by analyzing tumor images. - The AI identified that 25% of men with a specific biomarker saw their five-year death risk cut from 17% to 9% when taking abiraterone alongside standard therapy. - Men without the biomarker showed no statistically significant benefit from abiraterone, allowing doctors to spare them unnecessary treatment and side effects. - The breakthrough could enable NHS England to reconsider funding abiraterone for newly diagnosed high-risk prostate cancer that hasn't spread, potentially helping 2,100 men annually.
- IMU Biosciences has adopted Curiox's Pluto Workstation to support large-scale immune phenotyping within the £21.9 million MANIFEST consortium, the UK's largest immune profiling initiative. - The Pluto automation platform will enhance sample preparation quality and reproducibility for AI-driven immune profiling analytics, addressing critical challenges in traditional manual workflows. - The MANIFEST consortium aims to identify predictive biomarkers for cancer immunotherapy response, resistance, and immune-related adverse events through collaboration between 15 academic institutions and 11 industry partners.
- An international Phase 3 trial shows pembrolizumab (Keytruda) added to standard therapy extends disease-free survival from 30 to 51.8 months in patients with locally advanced head and neck cancer. - The immunotherapy treatment demonstrated greater tumor shrinkage prior to surgery and showed particular efficacy in patients with high PD-L1 levels, potentially changing standard care for the first time in over 20 years. - If approved by the FDA in June, pembrolizumab would represent the first significant advancement in treatment protocol for locally advanced head and neck cancer in more than two decades.
- AstraZeneca's experimental drug camizestrant reduced the risk of disease progression or death by 56% in patients with hormone receptor-positive, HER2-negative breast cancer when guided by liquid biopsy testing. - The SERENA-6 Phase III trial demonstrated that switching to camizestrant upon detection of ESR1 mutations extended median progression-free survival to 16 months compared to 9.2 months with standard therapy. - This represents the first global trial to show that using circulating tumor DNA blood tests to guide treatment changes before clinical progression has significant clinical benefit for breast cancer patients. - The study establishes a new treatment paradigm where resistance can be detected and addressed proactively, potentially delaying the need for chemotherapy and keeping patients on first-line therapy longer.
- A novel three-drug combination of inavolisib, palbociclib, and fulvestrant significantly extends progression-free survival in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer. - The INAVO120 trial demonstrated that the triple therapy delayed disease progression by an average of 15 months compared to 7.3 months with palbociclib and fulvestrant plus placebo. - After 18 months, 46.2% of patients on the inavolisib combination showed no disease progression, versus 21.1% in the placebo group, marking a potential 'transformative advance'. - The FDA has already approved the three-drug regimen, and researchers anticipate it becoming a standard of care pending licensing in other regions.
• A novel three-drug combination, including inavolisib, has demonstrated a doubling of survival time in patients with advanced breast cancer compared to standard treatments. • The international trial involved 325 patients, many with cancer spread to multiple organs, highlighting the potential of this regimen in challenging cases. • The combination therapy includes inavolisib along with two drugs already available, potentially facilitating quicker adoption into clinical practice. • Researchers from the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust led the study, marking a significant advancement in breast cancer treatment.
- The UK government is investing in new technologies, including AI, to improve cancer detection and treatment, aiming to boost the life sciences industry. - New partnerships between the NHS, pharmaceutical companies, and universities will trial innovative approaches for faster cancer diagnoses and better treatments. - Funding of £118 million will establish five new health technology hubs across the UK, fostering collaboration between academia and the private sector. - The investments also focus on personalized treatments and utilizing patient data to train AI models for quicker and more accurate cancer diagnoses.
